{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:54:36Z","timestamp":1771016076699,"version":"3.50.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1097\/md.0000000000000671","type":"journal-article","created":{"date-parts":[[2015,5,7]],"date-time":"2015-05-07T14:19:49Z","timestamp":1431008389000},"page":"e671","source":"Crossref","is-referenced-by-count":13,"title":["Is Administration of Trastuzumab an Independent Risk Factor for Developing Osteonecrosis of the Jaw Among Metastatic Breast Cancer Patients Under Zoledronic Acid Treatment?"],"prefix":"10.1097","volume":"94","author":[{"given":"Kezban Nur","family":"Pilanci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gul","family":"Alco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cetin","family":"Ordu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dauren","family":"Sarsenov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filiz","family":"Celebi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep","family":"Erdogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filiz","family":"Agacayak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serkan","family":"Ilgun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coskun","family":"Tecimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gokhan","family":"Demir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yesim","family":"Eralp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sait","family":"Okkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahit","family":"Ozmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210309","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies.","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"R2-1-20210309","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. A randomized, double-blind, multicenter, comparative trial.","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"issue":"suppl 12","key":"R3-1-20210309","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates.","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"R4-1-20210309","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","article-title":"Management of the adverse effects associated with intravenous bisphosphonates.","volume":"17","author":"Tanvetyanon","year":"2006","journal-title":"Ann Oncol"},{"key":"R5-1-20210309","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1016\/j.joms.2009.07.097","article-title":"American Association of Oral and Maxillofacial Surgeons position paper: bisphosphonate related osteonecrosis of the jaws2009 update: the need to refine the BRONJ definition.","volume":"67","author":"Colella","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"R6-1-20210309","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.","volume":"24","author":"Badros","year":"2006","journal-title":"J Clin Oncol"},{"key":"R7-1-20210309","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.joms.2007.03.006","article-title":"Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.","volume":"65","author":"Wang","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"R8-1-20210309","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"R9-1-20210309","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"R10-1-20210309","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/hed.20941","article-title":"Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws.","volume":"31","author":"Stumpe","year":"2009","journal-title":"Head Neck"},{"key":"R11-1-20210309","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ygyno.2008.11.029","article-title":"Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies.","volume":"112","author":"Fehm","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R12-1-20210309","first-page":"8580","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.","volume":"23","author":"Bamias","year":"2005","journal-title":"Clin Oncol"},{"key":"R13-1-20210309","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical OncologyCollege of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.","volume":"25","author":"Wolff","year":"2007","journal-title":"J Clin Oncol"},{"key":"R14-1-20210309","first-page":"1973","article-title":"A case of the lower jaw due to bisphosphonates in a breast cancer patient with bone metastasis.","volume":"35","author":"Kubo","year":"2008","journal-title":"Gan to Kagaku Ryoto"},{"key":"R15-1-20210309","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12282-008-0066-8","article-title":"A case of osteonecrosis of the jaw in a breast cancer patient with bone metastases receiving long-term treatment with bisphosphonates.","volume":"16","author":"Mouri","year":"2009","journal-title":"Breast Cancer"},{"key":"R16-1-20210309","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables.","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Ser B"},{"key":"R17-1-20210309","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"R18-1-20210309","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonates-induced exposed bone (osteonecrosisosteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.","volume":"63","author":"Marx","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"R19-1-20210309","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/416279b","article-title":"Tumour biology: herceptin acts as an anti-angiogenic cocktail.","volume":"416","author":"Izumi","year":"2002","journal-title":"Nature"},{"key":"R20-1-20210309","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.1038\/sj.onc.1209685","article-title":"HER2 signaling modulates the equilibrium between pro- and antiangiogenetic factors via distinct pathways: implications for HER2-targeted antibody therapy.","volume":"25","author":"Wen","year":"2006","journal-title":"Oncogene"},{"key":"R21-1-20210309","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone.","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"R22-1-20210309","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00784-009-0293-1","article-title":"Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw A prospective clinical study.","volume":"14","author":"Stockmann","year":"2010","journal-title":"Clin Oral Investig"},{"key":"R23-1-20210309","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica"},{"key":"R24-1-20210309","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1200\/JCO.2008.16.9300","article-title":"Natural history of osteonecrosis of the jaw in patients with multiple myeloma.","volume":"26","author":"Badros","year":"2008","journal-title":"J Clin Oncol"},{"key":"R25-1-20210309","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.oooo.2013.02.001","article-title":"Osteonecrosis of the mandible associated with bevacizumab therapy.","volume":"115","author":"Santos-Silva","year":"2013","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"R26-1-20210309","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.tripleo.2011.06.023","article-title":"Sunitinib-related osteonecrosis of jaw: a case report.","volume":"113","author":"Fleissig","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"R27-1-20210309","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/j.bjoms.2013.09.008","article-title":"Osteonecrosis of the jaw related to everolimus: a case report.","volume":"51","author":"Kim","year":"2013","journal-title":"Br J Oral Maxillofac Surg"},{"key":"R28-1-20210309","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.","volume":"23","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res"},{"key":"R29-1-20210309","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/bjc.2012.385","article-title":"Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.","volume":"107","author":"Beuselinck","year":"2012","journal-title":"Br J Cancer"},{"key":"R30-1-20210309","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.tripleo.2010.04.049","article-title":"Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases.","volume":"110","author":"Hoefert","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"R31-1-20210309","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2008.08.132","article-title":"Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma.","volume":"44","author":"Brunello","year":"2009","journal-title":"Bone"},{"key":"R32-1-20210309","first-page":"600","article-title":"Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile Ann O","volume":"20","author":"Ayllon","year":"2009","journal-title":"ncol"},{"key":"R33-1-20210309","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000313680","article-title":"Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib.","volume":"33","author":"Bozas","year":"2010","journal-title":"Onkologie"},{"key":"R34-1-20210309","first-page":"952","article-title":"Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports.","volume":"16","author":"Agrillo","year":"2012","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R35-1-20210309","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab.","volume":"26","author":"Estilo","year":"2008","journal-title":"J Clin Oncol"},{"key":"R36-1-20210309","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy.","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000000671","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T21:00:06Z","timestamp":1748379606000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201505020-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":36,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000000671","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}